IP Library Granted Patent US 11,241,409
Granted Patent B2
US 11,241,409 · App. 16/171,901 · Granted Feb 8, 2022

Neurodegenerative disorders and muscle diseases implicating PUFAs

Inventor: Mikhail S. Shchepinov (Kingston Upon Thames, GB)
Assignee: Retrotope, Inc.
A61K31/232A61K31/122A61K31/20A61K31/201A61K31/202A61K31/231A61K31/355A61K31/375A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,241,409
App. No.
16/171,901
Granted
Feb 8, 2022
Kind
B2
Abstract

Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and/or Multiple Sclerosis using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.

Claims (11)

1. A method for treating or inhibiting the progression of Alzheimer's Disease, Mild Cognitive Impairment, or Frontotemporal Dementia, comprising:

administering an effective amount of a deuterated polyunsaturated fatty acid or fatty acid ester to a patient suffering from Alzheimer's Disease, Mild Cognitive Impairment, or Frontotemporal Dementia,

wherein said deuterated polyunsaturated fatty acid of fatty acid ester is selected from the group consisting of 11,11-D2-linolenic acid, 14,14-D2-linolenic acid, 11,11,14,14-D4-linolenic acid, 11,11-D2-linoleic acid, 14,14-D2-linoleic acid, 11,11,14,14-D4-linoleic acid, 11-D-linolenic acid, 14-D-linolenic acid, 11,14-D2-linolenic acid, 11-D-linoleic acid, 14-D-linoleic acid, 11,14-D2-linoleic acid, and an ester of any of the foregoing, and combinations thereof, and

wherein said deuterated polyunsaturated fatty acid of fatty acid ester is incorporated into the body after administration.

2. The method of claim 1 , wherein the patient has Alzheimer's Disease.

3. The method of claim 1 , wherein the patient has Mild Cognitive Impairment.

4. The method of claim 1 , wherein the patient has Frontotemporal Dementia.

5. The method of claim 1 , wherein the deuterated polyunsaturated fatty acid ester is selected from an alkyl ester, a triglyceride, a diglyceride, a monoglyceride, and combinations thereof.

6. The method of claim 1 further comprising co-administering at least one antioxidant.

7. The method of claim 6 , wherein the antioxidant is selected from the group consisting of coenzyme Q, idebenone, mitoquinone, mitoquinol, Vitamin C, Vitamin E, and combinations thereof.

8. The method of claim 1 , wherein the amount of deuterated polyunsaturated fatty acid or fatty acid ester administered to the patient is in the range of from about 0.1 mg/kg to 100 mg/kg per day.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Sep 9, 2022
From: RTMFP ENTERPRISES INC.
To: RETROTOPE, INC.
Reel/Frame 061403/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2022
From: RETROTOPE, INC.
To: RTMFP ENTERPRISES INC.
Reel/Frame 061403/0835 →
CHANGE OF NAME Recorded Sep 9, 2022
From: RTMFP ENTERPRISES INC.
To: BIOJIVA LLC
Reel/Frame 061405/0819 →
SECURITY INTEREST Recorded Mar 30, 2022
From: RETROTOPE, INC.
To: RTMFP ENTERPRISES, INC.
Reel/Frame 059442/0414 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2021
From: SHCHEPINOV, MIKHAIL SERGEEVICH
To: RETROTOPE, INC.
Reel/Frame 057777/0993 →
Continuity (4)
Division 14113542
Provisional Application 61479269 · Apr 26, 2011
Provisional Application 61479270 · Apr 26, 2011
Related Publication 20190231733A1 · Aug 1, 2019